Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy is prescribed at increasing dose levels over several months, starting at 0.25mg and rising to either 2.4mg or the newer 7.2mg maintenance dose — a once-weekly subcutaneous injection, titrated step by step by a prescriber based on your tolerance and progress. It is a prescription-only medicine; a clinician assesses suitability before any dose is issued or changed. If you've just been told you're being moved up a level, or you're trying to understand what to expect at each stage, the picture below should help.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Almost everyone on Wegovy begins at the lowest level. The first pen isn't there to drive weight loss; its job is to let your gut adapt to semaglutide before the dose climbs. Nausea is the most common reason people stop GLP-1 treatment early, and the slow-start schedule exists specifically to reduce that risk. Four weeks at 0.25mg, four weeks at 0.5mg, and so on, the body generally tolerates the next level better because the previous one has already changed how your stomach empties and how your brain reads hunger signals. If you're feeling impatient at week two, that's understandable. Most people describe the early weeks as anticlimactic. But clinical experience is consistent on this: rushing the schedule trades short-term satisfaction for a much harder time later. Your prescriber sets the pace, and a pharmacist or prescriber can answer specific questions about what your current level should feel like. If you want to understand how a Wegovy prescription works and what the titration process looks like from the start, that page covers what to expect alongside how the medicine works during titration.
The five main levels split broadly into two groups. Doses up to 1.0mg are stepping stones; 1.7mg and 2.4mg are where most people stay long term, with 2.4mg the standard maintenance dose in clinical trials. In the STEP 1 trial, published in the New England Journal of Medicine, participants on 2.4mg achieved an average body-weight reduction of around 15% over 68 weeks alongside lifestyle changes. In April 2026, the MHRA approved a dedicated single-dose 7.2mg pen (one pre-set weekly injection) for adults with obesity (BMI of 30 or above). Trials at this higher level reported average weight loss of around 20.7% over 72 weeks, approaching results seen with tirzepatide at its highest doses. The 7.2mg level is the maximum; it is reached via the same step-by-step titration from 0.25mg. Jumping directly to a higher maintenance level is not how this medicine works. If you're comparing what different prescription levels might mean for your own situation, the Wegovy cost context page is worth reading alongside this one, prescription level affects how much you'll pay privately each month.
Prescribers consider several things when deciding whether to move someone to the next level: how well the current dose is tolerated, what side effects (if any) are present, and whether weight loss is progressing as expected. NICE guidance on semaglutide, published as TA875, notes that if someone has achieved less than 5% weight loss after six months on the maintenance dose, continuing treatment should be reconsidered, which is a useful marker for understanding what the upper levels are meant to deliver. In practice, some people stay at 1.7mg if 2.4mg causes side effects that don't settle. Others move through the schedule faster if tolerance is good. Neither path is wrong. What matters is that a real clinician is reviewing the picture, at nume, every repeat order is looked at by a GPhC-registered prescriber before anything is dispensed, and dose increases require clinical evidence rather than simply being requested. If you're unsure whether your current level is right, the process for getting a Wegovy prescription reviewed explains what that assessment involves.
Each step up typically brings a short recurrence of GI side effects (nausea, loose stools, or a change in appetite) as the body adjusts again. These usually settle within a week or two. The NHS semaglutide page lists the common side effects clearly and is worth bookmarking for reference. More serious symptoms (severe, persistent stomach pain that spreads toward the back, signs of an allergic reaction, or mood changes) need prompt medical attention and should not be attributed to dose adjustment without speaking to a clinician. Yellow Card reporting at yellowcard.mhra.gov.uk is the right route for any suspected serious reaction. The key thing to understand about dose levels is that they are not a ladder to climb as quickly as possible. Each one is a calibrated step, set by regulation and refined by clinical trial data. If you're thinking about starting Wegovy and want to understand how getting a Wegovy prescription online works, or want to know what separates a legitimate route from non-prescription Wegovy sources, speaking to our prescribers is the place to begin.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.